



Advanced Cancer Diagnosis and Treatment

Guest Editors:

Dr. Takaaki Hirotsu

Center of Medical Innovation and
Translational Research, Osaka
University Graduate School of
Medicine, Suita, Yamadaoka 2-2,
Osaka 565-0871, Japan

Prof. Dr. Hideshi Ishii

Department of Frontier Science
for Cancer and Chemotherapy,
Osaka University, Suita, Japan

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editors

Acknowledging the significant efforts made in combatting cancer, from academia to the private sector, in this Special Issue, we are seeking submissions of original research articles or reviews that present impactful advances in the development of cancer biology, diagnostics, and therapeutics on one or more of, but not limited to, the following topics:

- Cancer biology;
- Molecular mechanisms of cancers;
- Cancer epigenetics;
- Mechanism of resistance to conventional therapies;
- Cancer biomarkers;
- Early detection of cancers;
- Clinical investigations;
- Diagnostics of cancers;
- Novel therapeutics;
- Novel paradigms in the diagnosis and treatment of cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)